The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain

Article Oncology

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Eva Versteijne et al.

Summary: This study investigates the impact of neoadjuvant chemoradiotherapy on the survival of patients with resectable and borderline resectable pancreatic cancer. The results demonstrate that neoadjuvant chemoradiotherapy improves overall survival compared to upfront surgery in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Surgery

Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy

Shimpei Maeda et al.

Summary: The pathological treatment effect after resection is associated with prognosis for patients with localized pancreatic adenocarcinoma who received neoadjuvant therapy. Patients who received chemoradiotherapy had a better treatment effect compared to those who received chemotherapy alone, although the median overall survival was similar.

SURGERY (2022)

添加到收藏夹

Meeting Abstract Oncology

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.

Matthew H. G. Katz et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma A Phase 2 Randomized Clinical Trial

Davendra P. S. Sohal et al.

Summary: This study aimed to evaluate the 2-year overall survival rate of perioperative chemotherapy for resectable pancreatic ductal adenocarcinoma (PDA), but did not show significant improvement compared to historical data. The 2-year overall survival rates were 47% and 48% for the two treatment arms, demonstrating adequate safety and high resectability rates with perioperative chemotherapy, as well as challenges in quality control for resectability criteria.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology